Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...